512회
페이지 정보
작성자 : 관리자 날짜 : 작성일16-11-17 23:13 조회 : 3,397회본문
제 511 회 생명과학연구소 정기세미나 2016. 11. 17 목요일 오후5시 (자5 101호) |
Unraveling the molecular mechanisms underlying biliary-driven liver regeneration using zebrafish as a model organism
신 동헌 교수 (피츠버그 대학교)
As to the origin of regenerated hepatocytes, there are two types of liver regeneration: hepatocyte- and biliary-driven liver regeneration. Upon liver injury or resection, hepatocytes proliferate to recover the lost liver mass. However, if hepatocyte proliferation is compromised, as observed in chronic liver diseases, biliary epithelial cells (BECs) contribute to hepatocytes. In order to promote liver regeneration in the diseased liver as therapeutics, it is crucial to understand the molecular mechanisms underlying biliary-driven liver regeneration. Toward this goal, we have established a zebrafish liver regeneration model in which upon massive hepatocyte loss, BECs extensively contribute to hepatocytes. Using this model, we performed a targeted chemical screen to identify important factors that regulate BEC-driven liver regeneration. So far, we have screened 69 compounds and reported that the treatment of bromodomain and extraterminal domain (BET) inhibitors, JQ1 and iBET151, impaired multiple steps of BEC-driven liver regeneration. We also found that the treatment of the Bmp inhibitor, DMH1, and the histone deacetylase (HDAC) inhibitor, MS-275, impaired BEC-driven liver regeneration. These findings from pharmacological approaches were validated from genetic approaches. Furthermore, we found a compound that can promote BEC-driven liver regeneration. The treatment of the MEK1/2 inhibitor, U0126, increased the size of the regenerating liver and facilitated hepatocyte formation from BECs. Our findings provide examples of how the zebrafish liver regeneration model contributes to a better understanding of BEC-driven liver regeneration. This model will not only further contribute to the mechanistic understanding of BEC-driven liver regeneration but also lead to significant insights into promoting liver regeneration in patients with chronic liver diseases as therapeutics.
EDUCATION, TRAINING and APPOINMENTS
Undergraduate 1989-1995 (B.A.) Department of Molecular Biology, Seoul National University, Seoul, Korea
Graduate 1995-1997 (M.S.) Department of Molecular Biology, Seoul National University, Seoul, Korea
Graduate 1998-2005 (Ph.D.) Division of Biology, California Institute of Technology, Pasadena, CA
Postdoctoral Training 2005-2010 University of California, San Francisco, CA
Assistant Professor 2010 ~ 2016 University of Pittsburgh School of Medicine
Associate Professor 2016 ~ present University of Pittsburgh School of Medicine